Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Identifieur interne : 000892 ( PubMed/Corpus ); précédent : 000891; suivant : 000893Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Auteurs : Haggar H. Ampadu ; Jarno Hoekman ; Marieke L. De Bruin ; Shanthi N. Pal ; Sten Olsson ; Daniele Sartori ; Hubert G M. Leufkens ; Alexander N O. DodooSource :
- Drug safety [ 1179-1942 ] ; 2016.
English descriptors
- KwdEn :
- Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Africa, Angiotensin-Converting Enzyme Inhibitors (adverse effects), Anti-HIV Agents (adverse effects), Databases, Pharmaceutical, Female, Humans, Male, Middle Aged, Pharmacovigilance, Reverse Transcriptase Inhibitors (adverse effects), Young Adult.
- MESH :
Abstract
Following the start of the World Health Organization (WHO) Programme for International Drug Monitoring (PIDM) by 10 member countries in 1968, it took another 24 years for the first two African countries to join in 1992, by which time the number of member countries in the PIDM had grown to 33. Whilst pharmacovigilance (PV), including the submission of individual case safety reports (ICSR) to VigiBase(®), the WHO global ICSR database, is growing in Africa, no data have been published on the growth of ICSR reporting from Africa and how the features of ICSRs from Africa compare with the rest of the world (RoW).
DOI: 10.1007/s40264-015-0387-4
PubMed: 26754924
Links to Exploration step
pubmed:26754924Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.</title><author><name sortKey="Ampadu, Haggar H" sort="Ampadu, Haggar H" uniqKey="Ampadu H" first="Haggar H" last="Ampadu">Haggar H. Ampadu</name><affiliation><nlm:affiliation>WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, School of Medicine and Dentistry, University of Ghana, P.O Box GP 4236, Accra, Ghana. haggar.ampadu@who-pvafrica.org.</nlm:affiliation></affiliation></author><author><name sortKey="Hoekman, Jarno" sort="Hoekman, Jarno" uniqKey="Hoekman J" first="Jarno" last="Hoekman">Jarno Hoekman</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="De Bruin, Marieke L" sort="De Bruin, Marieke L" uniqKey="De Bruin M" first="Marieke L" last="De Bruin">Marieke L. De Bruin</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Pal, Shanthi N" sort="Pal, Shanthi N" uniqKey="Pal S" first="Shanthi N" last="Pal">Shanthi N. Pal</name><affiliation><nlm:affiliation>Safety and Vigilance, World Health Organization, Geneva, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Olsson, Sten" sort="Olsson, Sten" uniqKey="Olsson S" first="Sten" last="Olsson">Sten Olsson</name><affiliation><nlm:affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Sartori, Daniele" sort="Sartori, Daniele" uniqKey="Sartori D" first="Daniele" last="Sartori">Daniele Sartori</name><affiliation><nlm:affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name><affiliation><nlm:affiliation>WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, School of Medicine and Dentistry, University of Ghana, P.O Box GP 4236, Accra, Ghana.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26754924</idno><idno type="pmid">26754924</idno><idno type="doi">10.1007/s40264-015-0387-4</idno><idno type="wicri:Area/PubMed/Corpus">000892</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000892</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.</title><author><name sortKey="Ampadu, Haggar H" sort="Ampadu, Haggar H" uniqKey="Ampadu H" first="Haggar H" last="Ampadu">Haggar H. Ampadu</name><affiliation><nlm:affiliation>WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, School of Medicine and Dentistry, University of Ghana, P.O Box GP 4236, Accra, Ghana. haggar.ampadu@who-pvafrica.org.</nlm:affiliation></affiliation></author><author><name sortKey="Hoekman, Jarno" sort="Hoekman, Jarno" uniqKey="Hoekman J" first="Jarno" last="Hoekman">Jarno Hoekman</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="De Bruin, Marieke L" sort="De Bruin, Marieke L" uniqKey="De Bruin M" first="Marieke L" last="De Bruin">Marieke L. De Bruin</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Pal, Shanthi N" sort="Pal, Shanthi N" uniqKey="Pal S" first="Shanthi N" last="Pal">Shanthi N. Pal</name><affiliation><nlm:affiliation>Safety and Vigilance, World Health Organization, Geneva, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Olsson, Sten" sort="Olsson, Sten" uniqKey="Olsson S" first="Sten" last="Olsson">Sten Olsson</name><affiliation><nlm:affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Sartori, Daniele" sort="Sartori, Daniele" uniqKey="Sartori D" first="Daniele" last="Sartori">Daniele Sartori</name><affiliation><nlm:affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name><affiliation><nlm:affiliation>WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, School of Medicine and Dentistry, University of Ghana, P.O Box GP 4236, Accra, Ghana.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Drug safety</title><idno type="eISSN">1179-1942</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Adverse Drug Reaction Reporting Systems</term><term>Africa</term><term>Angiotensin-Converting Enzyme Inhibitors (adverse effects)</term><term>Anti-HIV Agents (adverse effects)</term><term>Databases, Pharmaceutical</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pharmacovigilance</term><term>Reverse Transcriptase Inhibitors (adverse effects)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Anti-HIV Agents</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Adverse Drug Reaction Reporting Systems</term><term>Africa</term><term>Databases, Pharmaceutical</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pharmacovigilance</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Following the start of the World Health Organization (WHO) Programme for International Drug Monitoring (PIDM) by 10 member countries in 1968, it took another 24 years for the first two African countries to join in 1992, by which time the number of member countries in the PIDM had grown to 33. Whilst pharmacovigilance (PV), including the submission of individual case safety reports (ICSR) to VigiBase(®), the WHO global ICSR database, is growing in Africa, no data have been published on the growth of ICSR reporting from Africa and how the features of ICSRs from Africa compare with the rest of the world (RoW).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26754924</PMID><DateCreated><Year>2016</Year><Month>03</Month><Day>18</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.</ArticleTitle><Pagination><MedlinePgn>335-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-015-0387-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Following the start of the World Health Organization (WHO) Programme for International Drug Monitoring (PIDM) by 10 member countries in 1968, it took another 24 years for the first two African countries to join in 1992, by which time the number of member countries in the PIDM had grown to 33. Whilst pharmacovigilance (PV), including the submission of individual case safety reports (ICSR) to VigiBase(®), the WHO global ICSR database, is growing in Africa, no data have been published on the growth of ICSR reporting from Africa and how the features of ICSRs from Africa compare with the rest of the world (RoW).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this paper was to provide an overview of the growth of national PV centres in Africa, the reporting of ICSRs by African countries, and the features of ICSRs from Africa, and to compare ICSRs from Africa with the RoW.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The search and analysis interface of VigiBase(®)--VigiLyze(®)--was used to characterise ICSRs submitted by African countries and the RoW. The distribution of ICSRs by African countries was listed and characterised by anatomic therapeutic chemical (ATC) code, Medical Dictionary for Regulatory Activities (MedDRA(®)) system organ class (SOC) classification, and patient age and sex. The case-defining features of ICSRs between Africa and the RoW were also compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of African countries in the PIDM increased from 2 in 1992 to 35 at the end of September 2015, and African PIDM members have cumulatively submitted 103,499 ICSRs (0.88 % of global ICSRs) to VigiBase(®). The main class of products in African ICSRs are nucleoside and nucleotide reverse transcriptase inhibitors (14.04 %), non-nucleoside reverse transcriptase inhibitors (9.09 %), antivirals for the treatment of HIV infections (5.50 %), combinations of sulfonamides and trimethoprim (2.98 %) and angiotensin-converting enzyme (ACE) inhibitors (2.42 %). The main product classes implicated in ICSRs from the RoW are tumour necrosis factor-α (TNFα) inhibitors (5.29 %), topical nonsteroidal anti-inflammatory preparations (2.26 %), selective immunosuppressants (2.08 %), selective serotonin reuptake inhibitors (2.04 %) and HMG CoA reductase inhibitors (1.85 %). The main SOCs reported from Africa versus the RoW include skin and subcutaneous tissue disorders (31.14 % vs. 19.58 %), general disorders and administration site conditions (20.91 % vs. 30.49 %) and nervous system disorders (17.48 % vs. 19.13 %). The 18-44 years age group dominated ICSRs from Africa, while the 45-64 years age group dominated the RoW. Identical proportions of females (57 % Africa and the RoW) and males (37 % Africa and the RoW) were represented.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As at the end of September 2015, 35 of 54 African countries were Full Member countries of the PIDM. Although the number of ICSRs from Africa has increased substantially, ICSRs from Africa still make up <1 % of the global total in VigiBase(®). The features of ICSRs from Africa differ to those from the RoW in relation to the classes of products as well as age group of patients affected. The gender of patients represented in these ICSRs are identical.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ampadu</LastName><ForeName>Haggar H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, School of Medicine and Dentistry, University of Ghana, P.O Box GP 4236, Accra, Ghana. haggar.ampadu@who-pvafrica.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. haggar.ampadu@who-pvafrica.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoekman</LastName><ForeName>Jarno</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bruin</LastName><ForeName>Marieke L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Shanthi N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Safety and Vigilance, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Sten</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sartori</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leufkens</LastName><ForeName>Hubert G M</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodoo</LastName><ForeName>Alexander N O</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, School of Medicine and Dentistry, University of Ghana, P.O Box GP 4236, Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2015 Jun;20(6):797-806</RefSource><PMID Version="1">25704305</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2012 Sep 21;337(6101):1499-501</RefSource><PMID Version="1">22997329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2011 Jul;8(7):e1001054</RefSource><PMID Version="1">21750668</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Malar J. 2011;10:57</RefSource><PMID Version="1">21388536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Clin Pharm. 2014 Apr;36(2):352-9</RefSource><PMID Version="1">24366678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2014 Oct;37(10):743-59</RefSource><PMID Version="1">25171836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Res Social Adm Pharm. 2010 Dec;6(4):345-53</RefSource><PMID Version="1">21111391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2007 Sep 8;335(7618):462</RefSource><PMID Version="1">17823149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Clin Pharmacol. 2015;8(4):449-60</RefSource><PMID Version="1">26041035</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Adv Drug Saf. 2012 Feb;3(1):25-34</RefSource><PMID Version="1">25083223</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2008;31(10):867-76</RefSource><PMID Version="1">18759510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2015 Apr;38(4):395-408</RefSource><PMID Version="1">25749663</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int Health. 2015 Nov;7(6):390-9</RefSource><PMID Version="1">26103981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2012 Dec 1;35(12):1171-82</RefSource><PMID Version="1">23072620</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Saf. 2010 Aug 1;33(8):689-703</RefSource><PMID Version="1">20635827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull World Health Organ. 2014 Dec 1;92(12):918-9</RefSource><PMID Version="1">25552777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ Open. 2014;4(11):e005869</RefSource><PMID Version="1">25421337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ghana Med J. 2014 Dec;48(4):189-93</RefSource><PMID Version="1">25709133</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trans R Soc Trop Med Hyg. 2006 Mar;100(3):191-9</RefSource><PMID Version="1">16274715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1303-10</RefSource><PMID Version="1">21735508</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N">Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062313" MajorTopicYN="Y">Databases, Pharmaceutical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4796322</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26754924</ArticleId><ArticleId IdType="doi">10.1007/s40264-015-0387-4</ArticleId><ArticleId IdType="pii">10.1007/s40264-015-0387-4</ArticleId><ArticleId IdType="pmc">PMC4796322</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000892 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000892 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26754924
|texte= Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26754924" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |